# Symptoms and risk factors for hospitalization of COVID-19 presented in primary care:

## Preliminary results

Rabady S[1], Kamenski G[2], Brose M[3], Lammel O[4], Poggenburg S[5], Redlberger-Fritz M[6], Stiasny K[7], Wendler M[8], Weseslindtner L[9], Zehetmayer S[10], Hoffmann K[11].

Corresponding author:

Dr. Susanne Rabady

Email: susanne.rabady@kl.ac.at

Phone: +436641351091

[1] MD, Head of Department of General Practice and Family Medicine, Karl-Landsteiner Private University for Health Sciences, Karl-Dorrekstr.31 3500 Krems, Austria; ORCID-ID: https://orcid.org/0000-0002-3603-5841

[2] MD, Department of General Practice and Family Medicine, Karl-Landsteiner Private University for Health Sciences, Karl-Dorrekstr.31 3500 Krems, Austria; Karl Landsteiner Institute for Systematics in General Medicine, Angern, Austria ORCID ID: 0000-0002-9321-2293

[3] MD, Department of General Practice and Family Medicine, Karl-Landsteiner Private University for Health Sciences, Karl-Dorrekstr.31 3500 Krems, Austria ORCID-ID: 0000-0002-4902-4463

[4] MD, Praxis Dr Oliver Lammel, Ramsau am Dachstein. ORCID ID: 0000-0003-0641-7678

[5] MD, Ordination Dr. Stephanie Poggenburg, Hart bei Graz. ORCID ID: 0000-0002-6233-3455

[6] Doz.Dr, Center of Virology, Medical University Vienna, Vienna, Austria ORCID-ID 0000-0001-6265-557X

[7] Prof, Center of Virology, Medical University Vienna, Vienna, Austria ORCID-ID: 0000-0002-1902-8674

[8] MD Department of General Practice and Family Medicine, Karl-Landsteiner Private University for Health Sciences, Karl-Dorrekstr.31 3500 Krems, Austria

[9] Prof, Center of Virology, Medical University Vienna, Vienna, Austria ORCID-ID: 0000-0001-8950-937X

[10] assoc.Prof. Dr, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalg.23 1090 Vienna Orcid-ID: ORCID: 0000-0001-6863-7997

[11] assoc. Prof. Priv.-Doz. Dr., MPH, Associate Professor, Head of Unit Health Services Research and Telemedicine in Primary Care, Department of Preventive- and Social Medicine, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria; ORCID-ID: https://orcid.org/0000-0001-8760-4250

# Abstract

## Background

Early detection is essential to control COVID-19. Symptoms are often unspecific. Data collected merely from patients tested according to testing criteria might lead to missing a bulk of spreaders. Knowledge of symptom development during the disease helps to detect complications early. Few data have been collected in primary care so far.

## Aim

To extend knowledge of early symptoms as a precondition of timely diagnosis, isolation and contact tracing. To gain understanding of associations between symptoms and complicated disease to help avoid hospitalization.

## Design and Settings

This study was designed as a retrospective observational study in Austrian GP practices in the year 2020.

## Methods

Patients above 18 years with a positive SARS-CoV-2 test were included.
Data collection comprised basic demographic data, risk factors and the recording of symptoms at several points in time during the course of the infection. Further descriptive data analysis was carried out by using the statistical software program R.

## Results

Symptoms clearly typical for COVID-19 are rare. Most symptoms are nonspecific, like malaise, fatigue or joint ache. We found symptoms indicating complicated disease, depending on the time of their occurrence. Anosmia we found to develop only after several days in many cases. At the end of the isolation period many patients still experience symptoms.

## Conclusion

Low threshold contact in GP practices including testing can prevent overlooking early symptoms. Patients may benefit from early monitoring.   We recommend a medical check-up at the end of the isolation period.

## Keywords

Primary Care, COVID-19, symptoms, risk factors, diagnosis, monitoring

## How this fits in

Most testing strategies for COVID-19 are based on symptoms assumed to be typical for the disease. We found strong hints that in the general practice-setting patients frequently do not present any of the "typical" symptoms and, thus, might be overlooked by "traditional" testing strategies. It is those patients though, who are mobile enough to widely spread the disease. Identifying them early in the course of their disease is a requirement for effective containment strategies, e.g. "Test-Trace-Isolate".

## Introduction

A central aspect in the containment of the COVID19 pandemic is identification and isolation of possibly infectious persons, symptomatic and a- or presymptomatic, to prevent further spreading

of the disease. Several studies were conducted with the goal of identifying diagnostic criteria that allow clinical differentiation between Covid- and Non-Covid-infections: most investigations used data collected from hospitalized patients (1-6), thus from patients with severe disease. These studies have found high prevalence of fever (around 90%), dyspnoea (up to 50%), cough (60-70%), and fatigue in patients with COVID-19.  Several other studies evaluate self- reported data from symptom tracker apps or outpatient clinics (2, 7-10). We could find but one investigation including data additionally derived from primary care health records (9). Studies conducted in non-hospitalized patients reported a lower prevalence of the symptoms mentioned, and a wide spectrum of additional symptoms, like myalgia, rhinorrhoea and/or nasal congestion, headache, sore throat, gastrointestinal and cardiovascular disturbances (7-9, 11). Loss of taste and/or smell was found to be rather specific when present (8, 11). All patients included in those studies had gone through a selection process before testing – by case definitions and testing criteria, by epidemiologic factors or by previous other tests (i.e. imaging). Some of these studies included only patients that had tested positive (10), others investigated patients that had tested positive or negative (8, 9). Patients not fulfilling established criteria may have escaped testing, and the symptoms found may reflect testing criteria (7). Some authors suspect that possibly a large proportion of COVID-19 cases are never tested and, thus, never recorded (12). This has not been investigated so far.

### What this study can add

This study was conducted in primary care. Austrian GP practices are entitled to either test for SARS-CoV-2 on the point of care since mid-October 2020, or have their samples for SARS-CoV-2 PCR analyzed via a Surveillance Network based at the Medical University Vienna. 25% of our study practices were part of this network. So GPs were entitled to make an individual testing decision. GP practices in Austria are very easy to access, in general it is possible to just walk in or to get an appointment on the same day.

It was the aim of this study to assess early COVID19 symptoms and symptom combinations of patients in different demographic groups in primary care, as well as their possible associations with the course of the disease.

## Methods

This study was designed as an explorative, retrospective study in General Practice in Austria from July 2020 until January 2021. Recruitment of practices and participants took place between July 2020 and December 2020.

The Austrian Society of General Practice invited their members, publicly funded GPs and their practices, to participate. For this purpose, first announcements and invitation letters were sent out between 28th April and 23rd July 2020. After the positive votum of the ethics committee practices interested in participating were informed about the aims of this study in detail and after agreement study material was provided.

Participating GPs included patients above 18 years either after testing or receiving the positive PCR result, or after being contacted by them presenting a positive PCR test by phone or after the isolation period. These persons were informed about this study. If they were willing to participate and after the provision of their written informed consent, they were included in the study.

### Study material and data collection

A questionnaire using the open source CDC program Epi Info 7 was designed to record demographic and anamnestic data, comorbidities, medication groups and risk factors regarding

COVID19 Annex. Data extracted from the electronic health record (EHR) of the practice were transferred to the questionnaire. In addition, clinical parameters for assessing the patient's` health status over a period of two weeks starting with the date of positive test applied as day 1 were documented. Additional assessment days were day 5, 7, 8, 10 and 14. The data were either self reported via a previously submitted monitoring sheet by the patients, or via phone calls by the GPs. Data regarding patients` health status and symptoms were: temperature, blood pressure, heart rate, dyspnoea, chest pressure, tightness of chest, malaise, weakness, headache, rhinitis, anosmia, ageusia, sore throat or gastrointestinal symptoms Annex 2. These clinical parameters were selected using published studies of signs and symptoms of patients with COVID-19 (13, 14). All data were pseudonymized before forwarding them to the study centre. There, the data were checked for completeness and correct entries. Ambiguities were clarified by telephone call or e-mail contact with the participating GP practice.

## Data analysis
Data were converted into Excel files and accompanying statistical analysis was done using the statistical software program R (version 3.5.1).

Participants' demographics as well as symptoms were first analysed descriptively. Descriptive analyses for possible associations between demographics and symptoms were conducted by means of cross table. Group differences (hospitalized yes/no) were assessed with the Exact Fisher test , group comparison for number of symptoms with the Wilcoxon test. The significance level was set to 0.05, due to the exploratory character of the study, no adjustment for multiplicity was performed. Analysis was done using the statistical software program R (version 3.5.1).

Not all symptom fields had been completed for all patients, with values for temperature missing most often. Assuming that missing data could at least partly be interpreted as "symptom not present", we recalculated the tables setting missing values to "symptom not present". With the exception of fever, this procedure does neither change sequence nor rank Supplementary Table 2a.

## Results
Altogether, 22 GP practices and 154 patients from seven Austrian federal states could be recruited. On average, the practices included 7 patients (SD 5.97, min 2 - max 23).

Patients` demographics are described in Supplementary Table 1.

Slightly more women (n=82, 55.8%) than men (n=65, 44.2%) were included. The percentage of obese persons (BMI >30) was 12.5%, which is less than the Austrian average of 16% (15) and only 12 persons (8.6%) were smokers, clearly less than the Austrian average of 20% (16).

As can be seen in Supplementary Table 2, the most frequent out of 13 asked symptoms on day 1 was malaise (56%, n=83), followed by joint/muscle pain. From day 7 loss of smell/taste became the most frequent complaint and remains so until the end of the observational period on day 14. Fatigue was the 4th most prevalent symptom on day 1 (43.5%, n= 64), and the most frequent symptom on day five, and with 30.3% (n=36) still highly prevalent on day 10.  So, fatigue was found to be the most persistent of symptoms. Cough is a less frequent symptom on day 1 (6th of 13 symptoms, 33.8%, n=49), becoming more frequent from day 5 onwards. Fever was reported by slightly more than one-third of the patients Supplementary Table 2a

From day 5 onwards we found that fatigue, malaise and cough were each significantly associated with hospital admission. Dyspnoea on days 1, 10 and 14 also shows associations with

hospitalization. We found an association for fever only when present on day 5 (Supplementary Table 3). These values were alternatively calculated assuming that missing values correspond to "symptom not present", which made some difference in percentages but did not alter our findings substantially.

Supplementary Table 4 shows that COVID-19 seems to start with several symptoms simultaneously (most frequently: 3-5 symptoms).

60% (n=22) of those patients who completed the whole monitoring period still reported symptoms on day 14. A considerable number of patients dropped out, probably due to the fact that isolation ends on day 10 in Austria. Assuming that all patients who were lost to follow up were free of symptoms, it is still 31.2 % of the sample who do report persistent symptoms on day 10, and 14.3% on day 14.

A higher number of symptoms was associated with higher probability of hospital admission. This was significant for days 5 to 8 Supplementary Table 5.

# Discussion

## Summary

Early symptoms we found to be mostly unspecific and often discreet. We did not find any symptom to exclude or confirm early diagnosis of COVID-19 by clinical means alone.

Anosmia as the most specific symptom tends to appear in the later course of the disease. This finding should lead to reconsider contact tracing strategies: finding the symptom anosmia should prompt an extension of the contact tracing period to at least 8 days before the infection was detected.

We found several associations between symptoms and the need for hospitalization. Our findings suggest that dyspnoea is particularly prone to lead to complications when present on day 1, and on days 10 and 14 - less so if present on days 5,7, and 8.  We additionally detected a high number of 3 or more symptoms on day 5 and 7 to be associated with a higher probability of hospital admissions Supplementary Table 5. Fatigue as well as malaise through the whole course of disease starting from day 5, and cough, persisting from day 7 seem to be associated with higher rates of hospitalization, but fever only if present on day 5 Supplementary Table 2, Supplementary Table 2a. Those findings suggest that patients might profit from being closely monitored so that complications are recognised early and possibly avoided or mitigated.

A significant number of patients (at least 14.3%) reported symptoms at the end of the observational period on day 14, and at 31.2% on day 10, when the isolation period ends. Regarding the fact, that Long Covid is in a relevant proportion not a trivial complaint but may lead to delayed and severe complications (17), it seems justifiable to recommend a medical examination after isolation to decide if and when a patient can be considered healthy and safe to return to physical activity and/or work.

## Strengths and limitations of the study

This study to our knowledge is the first one to investigate data on the course of COVID-19 collected exclusively in a population presenting to primary care, predominantly (90%) unselected. Since we were not restricted to patients with a testing decision made beforehand like most other studies were, as elucidated by several studies (2, 7, 9, 10), we could follow the course of disease from day 1 in most cases. Only 10% approached primary care after having been tested according to testing criteria elsewhere. Those were followed retrospectively.

Being conducted in primary we could oversee a wide range of patients, including patients presenting for symptoms they had not expected to be signs of COVID-19, e.g. back pain, headache, weakness, or common cold.

The study has several limitations though. We could recruit 22 practices in 7 out of the 9 Austrian provinces. The practices included 7 (SD 5.9) patients on average into the study. This low response rate is probably due to the increased workload under difficult working conditions during the pandemic in combination with a rather extensive questionnaire and the need to follow patients over a period of time. Looking at this limited inclusion of positive cases we have to reckon with possible selection bias.

Another limitation is not all data on symptoms were provided, particularly on fever. Most likely this applies mainly for symptoms which were not present, but this would have to be clarified by further research. Some patients (approximately 10%) were not diagnosed in primary care, so a possible confounder testing criteria cannot be ruled out. We are likely to have overestimated some symptoms on day 1, because a proportion of patients may have been diagnosed later than day 1.

Due to the sample size, we had to refrain from looking closer into patterns of symptoms. The collection of extended data from patients in primary care might offer valuable insights and should be encouraged.

## Comparison with existing literature

We found early symptoms to be mostly unspecific: most frequent symptoms being malaise, joint- and/or muscle pain, headache, fatigue, and cough, all of which are experienced in a wide spectrum of other infectious diseases, which matches insights from other studies (7, 9). Symptoms generally considered to increase likelihood for Covid diagnosis: fever, dyspnoea and loss of taste and/or smell (7, 9, 10) (18, 19) we found to be comparatively rare though, at least at early stages of the disease Supplementary Table 2, Supplementary Table 2a, Supplementary Figure 1: on day 1 less than 30% of patients reported fever, less than one third (25.9%) reported loss of smell or taste, and only 13.6 % suffered from dyspnoea which renders the symptoms unsuitable as testing criteria. These results differ from other studies that had derived data from hospitalized patients exclusively (1, 20), or in combination with self reported data using symptom apps. All of them were conducted in patients that had been tested according to pre-established testing criteria (8, 10). Our findings suggest that neither presence nor absence of any symptom is suitable to rule out COVID-19, and confirm results from another study, showing that patients reporting whatever symptoms of infectious disease profit from testing without delay (21).

Our findings on anosmia are somewhat surprising : loss of smell/taste is reported by as little as 25.9% (n=40) of patients in our study on day 1 – but with increasing frequency in the course of the disease, reaching its peak on day 8 (47.2 %, n=58). It remains the most common symptom at least till day 14.  Menni (8) identified this symptom in 64.5% of patients, and concludes that this symptom could help early diagnosis. Our findings do not support this. The difference may be caused by the time of detection or selection bias and thus shows the relevance of early investigation of symptoms at a low threshold point of care (21).

Dyspnoea has been shown to be predictive for hospital admission in one systematic review and a metaanalysis (2, 22), which is in line with our findings. No other predictive symptoms have consistently been shown so far. Our findings on persisting symptoms fit in well with recent studies on persistent COVID-19 (23, 24).

## Implications for research and practice

Data collected in primary care settings can provide additional information and can offer a wider spectrum of understanding COVID-19 disease. The results of our exploratory retrospective study should be controlled by a prospective study.

We did not record data on patients who tested negative. Future investigations into this topic in primary care should aim at recording symptoms in all patients testing negative or positive.

Low threshold contact for patients with any kind of symptoms combined with testing at the point of care can accelerate the diagnosis and enhance effective contact tracing.

Patients might benefit from early monitoring even in seemingly mild or moderate cases, since there are symptoms indicating higher probability for complications.

Essential for successful monitoring is that Covid patients report to their GP. Information should be given to patients accordingly, or an automatism could be installed that ensures information transfer to the GPs` offices. At the end of the isolation period a medical check-up should be recommended to ensure safe return to physical strain.

## Additional information

### Funding
A grant was provided by the Styrian Academy of General Medicine, Graz.

### Ethical approval
was given by Commission for Scientific Integrity and Ethics, Karl-Landsteiner Private University for Health Sciences, Krems, Austria. EK Nr: 1046/2020 13/07/20

The study was registered as DRKS00022448 on DRKS

### Competing interests
None

### Acknowledgements
The Austrian Society of General Practice and Family Medicine provided support by assisting the process of recruitment of study practices. This was essential for this study to be undertaken.

We thank all our colleague GPs who undertook the task of recruiting patients, completing questionnaires and onward them to us.

And we thank the many patients, who contributed their data and recorded their symptoms.

## References

1.      Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
2.      Jain V, Yuan J-M. Systematic review and meta-analysis of predictive symptoms and comorbidities for severe COVID-19 infection. medRxiv. 2020:2020.03.15.20035360.
3.      Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
4.      Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect 2020;80(6):656-65.

5.        Sun P, Qie S, Liu Z, Ren J, Xi J. Clinical characteristics of 50466 patients with 2019-nCoV infection. medRxiv. 2020:2020.02.18.20024539.

6.        Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020.

7.        Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev. 2021;2:Cd013665.

8.        Menni C, Sudre CH, Steves CJ, Ourselin S, Spector TD. Quantifying additional COVID-19 symptoms will save lives. Lancet. 2020;395(10241):e107-e8.

9.        Mizrahi B, Shilo S, Rossman H, et al. Longitudinal symptom dynamics of COVID-19 infection. Nat Commun. 2020;11(1):6208.

10.        Huang Y, Radenkovic D, Perez K, et al. Age-dependent and Independent Symptoms and Comorbidities Predictive of COVID-19 Hospitalization. medRxiv. 2020:2020.08.14.20170365.

11.        Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;26(7):1037-40.

12.        Alvarez E, Marsico F. COVID-19 mild cases determination from correlating COVID-line calls to reported cases. 2020. medRxiv 2020.07.26.20162008

13.        Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. Bmj. 2020;368:m1182.

14.        Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.

15.        Statista Austria BMI . Available from: http://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/gesundheit/gesundheitsdeterminanten/bmi_body_mass_index/025420.html (accessed 8 March 2021)

16.        Statista Austria Smoking. Available from: https://de.statista.com/statistik/daten/studie/510314/umfrage/anteil-der-raucher-gelegenheits-ehemaligen-und-nichtraucher-in-oesterreich/ (accessed 6 March 2021)

17.        Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.

18.        Case definition Austria. Available from: https://www.sozialministerium.at/Themen/Gesundheit/Uebertragbare-Krankheiten/Infektionskrankheiten-A-Z/Neuartiges-Coronavirus.htmlpatients (accessed 5 March 2021)

19.        Case definition bmj  [08.03.2021]. https://bestpractice.bmj.com/topics/en-gb/3000201/criteria

20.        Larsen JR, Martin MR, Martin JD, Kuhn P, Hicks JB. Modeling the Onset of Symptoms of COVID-19. Front Public Health. 2020;8(473).

21.        Leber W, Lammel O, Redlberger-Fritz M, et al. RT-PCR testing to detect a COVID-19 outbreak in Austria: rapid, accurate and early diagnosis in primary care (The REAP study). medRxiv. 2020:2020.07.13.20152439.

22.        Mudatsir M, Fajar J, Wulandari L, et al. Predictors of COVID-19 severity: a systematic review and meta-analysis [version 1; peer review: 1 approved]. F1000Research. 2020;9(1107).

23.        Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv. 2020:2020.10.19.20214494.

24.        Sivan M, Taylor S. NICE guideline on long covid. BMJ. 2020;371:m4938.

## Table S1 Demographics

| variable | categories | percentage | frequency |
|---|---|---|---|
| sex (n=147) | female | 55.8 | 82 |
|  | male | 44.2 | 65 |
| age (n=141) | 16-30 | 19.1 | 27 |
|  | 31-50 | 34.8 | 49 |
|  | 51-70 | 39.0 | 55 |
|  | 71+ | 7.1 | 10 |
| BMI (n=72) | 18-24 | 51.4 | 37 |
|  | 25-29 | 36.1 | 26 |

COVID-19 in primary care - symptoms, risk factors

|  | 30+ | 12.5 | 9 |
|---|---|---|---|
| smoking (n=140) | yes | 8.6 | 12 |
|  | no | 91.4 | 128 |

Table S2    Symptoms reported on day 1,5,7,8,10,14

| symptom present | day 1 % (n) | day 5 % (n) | day 7 % (n) | day 8 % (n) | day 10 % (n) | day 14 % (n) |
|---|---|---|---|---|---|---|
| fever | 38.7 (46) | 29.4 (32) | 16.0 (15) | 16.4 (12) | 9.4 (6) | 3.4 (2) |
| dyspnoea | 14.3 (21) | 18.4 (26) | 13.3 (18) | 13.1 (16) | 12.7 (15) | 10.1 (12) |
| malaise | 56.5 (83) | 40.6 (58) | 34.8 (47) | 30.9 (38) | 21.0 (25) | 8.4 (10) |
| fatigue | 43.5 (64) | 40.6 (58) | 37.8 (51) | 35.8 (44) | 30.3 (36) | 14.3 (17) |
| headache | 46.6 (68) | 28.0 (40) | 19.3 (26) | 13.8 (17) | 12.7 (15) | 5.1 (6) |
| joint/muscle pain | 48.3 (71) | 36.4 (52) | 28.1 (38) | 22.8 (28) | 15.3 (18) | 5.9 (7) |
| rhinitis | 21.4 (31) | 15.4 (22) | 10.4 (14) | 11.4 (14) | 6.7 (8) | 2.5 (3) |
| cough | 33.8 (49) | 37.6 (53) | 35.1 (46) | 32.2 (39) | 24.1 (28) | 19.0 (22) |
| chest pain | 11.6 (17) | 13.5 (19) | 12.0 (16) | 10.7 (13) | 8.4 (10) | 3,4 (4) |
| tightness of chest | 10.3 (15) | 11.3 (16) | 14.2 (19) | 10.7 (13) | 7.6 (9) | 3.4 (4) |
| anosmia / ageusia | 27.6 (40) | 37.8 (54) | 41.5 (56) | 47.2 (58) | 42.0 (50) | 32.2 (38) |
| gastrointestinal symptoms | 16.4 (24) | 16.9 (24) | 8.2 (11) | 8.2 (10) | 5.9 (7) | 2.6 (3) |
| sore throat | 28.3 (41) | 16.4 (23) | 8.4 (11) | 8.9 (11) | 6.8 (8) | 1.7 (2) |

*Colour coding according to frequency (descending): dark red – red - dark yellow – yellow – light yellow.*

Table S2a   Symptoms reported on day 1,5,7,8,10,14, calculated assuming that symptoms  not reported were not present.

| symptom present | day 1 % (n) | day 5 % (n) | day 7 % (n) | day 8 % (n) | day 10 % (n) | day 14 % (n) |
|---|---|---|---|---|---|---|
| fever | 29.8 (46) | 20.7 (32) | 10.4 (15) | 7.8 (12) | 3.9 (6) | 1.3 (2) |
| dyspnoea | 13.63 (21) | 16.8 (26) | 11.7 (18) | 10.4 (16) | 9.7 (15) | 7.8 (12) |
| malaise | 53.89 (83) | 37.66 (58) | 30.5 (47) | 24.7 (38) | 16.2 (25) | 6.5 (10) |
| fatigue | 41.5 (64) | 37.66 (58) | 33.1 (51) | 28.6 (44) | 23.4 (36) | 11.0 (17) |
| headache | 44.1 (68) | 25.8 (40) | 16.9 (26) | 11.1 (17) | 9.7 (15) | 3.9 (6) |
| joint/muscle pain | 46.10 (71) | 36.4 (52) | 24.7(38) | 18.2 (28) | 11.7 (18) | 4.5 (7) |
| rhinitis | 20.1 (31) | 15.4 (22) | 9.1 (14) | 9.1 (14) | 5.2 (8) | 1.9 (3) |
| cough | 31.8 (49) | 33.7 (53) | 29.9 (46) | 25.3 (39) | 18.2 (28) | 14.3 (22) |
| chest pain | 11.1 (17) | 12.34 (19) | 10.4 (16) | 8.4 (13) | 6.5 (10) | 2.6 (4) |
| tightness of chest | 9.7 (15) | 10.4 (16) | 12.3 (19) | 8.4 (13) | 5.8 (9) | 2.6 (4) |
| anosmia / ageusia | 25.9 (40) | 35.1 (54) | 36.4 (56) | 37.7 (58) | 32.5 (50) | 24.7 (38) |
| gastrointestinal symptoms | 15.6 (24) | 15.6 (24) | 7.1 (11) | 6.5 (10) | 4.5 (7) | 1.9 (3) |
| sore throat | 26.6 (41) | 14.9 (23) | 7.1 (11) | 7.1 (11) | 5.2 (8) | 1.3 (2) |

*Colour coding according to frequency (descending): dark red – red - dark yellow – yellow – light yellow.*

Table S3   Hospital admission vs. non-admission in relation to the presence of a symptom

| | day 1: n (%) | | | day 5: n (%) | | | day 8: n (%) | | | day 10: n (%) | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| symptom present | No. Hosp. | Hosp. | p | No. Hosp. | Hosp. | p | No. Hosp. | Hosp. | p | No. Hosp. | Hosp. | p |
| fever | 40 (36.4) | 7 (50.0) | 0.385 | 26 (25.5) | 9 (69.2) | 0.003 | 11 (15.9) | 4 (40.0) | 0.089 | 5 (8.2) | 3 (33.3) | 0.060 |
| dyspnoea | 16 (11.9) | 5 (33.3) | 0.040 | 22 (16.9) | 5 (33.3) | 0.157 | 13 (11.4) | 4 (33.3) | 0.057 | 11 (10.0) | 4 (33.3) | 0.041 |
| malaise | 73 (53.7) | 12 (80.0) | 0.059 | 47 (35.6) | 13 (86.7) | <0.001 | 30 (26.1) | 11 (84.6) | <0.001 | 21 (18.8) | 6 (50.0) | 0.022 |

COVID-19 in primary care - symptoms, risk factors

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| fatigue | 57 (41.6) | 11 (73.3) | 0.027 | 50 (37.0) | 12 (80.0) | 0.002 | 36 (30.8) | 11 (84.6) | <0.001 | 32 (28.1) | 9 (75.0) | 0.002 |
| headache | 65 (48.1) | 7 (43.8) | 0.796 | 35 (26.5) | 8 (50.0) | 0.077 | 13 (11.3) | 5 (38.5) | 0.020 | 10 (9.1) | 5 (41.7) | 0.007 |
| joint/muscle pain | 68 (49.6) | 8 (50.0) | 1.000 | 50 (37.3) | 7 (43.8) | 0.600 | 26 (22.4) | 5 (35.7) | 0.320 | 17 (15.3) | 4 (30.8) | 0.232 |
| rhinitis | 29 (21.8) | 2 (14.3) | 0.735 | 20 (15.3) | 2 (13.3) | 1.000 | 12 (10.5) | 2 (15.4) | 0.636 | 6 (5.4) | 2 (16.7) | 0.176 |
| cough | 42 (31.8) | 9 (56.2) | 0.091 | 46 (35.1) | 11 (68.8) | 0.013 | 33 (28.9) | 10 (71.4) | 0.005 | 24 (21.8) | 8 (61.5) | 0.005 |
| chest pain | 17 (12.8) | 1 (6.7) | 0.695 | 20 (15.5) | 1 (6.7) | 0.698 | 13 (11.5) | 2 (15.4) | 0.654 | 12 (10.8) | 0 (0.0) | 0.605 |
| tightness of chest | 13 (9.7) | 3 (20.0) | 0.206 | 14 (10.6) | 4 (26.7) | 0.090 | 13 (11.4) | 3 (23.1) | 0.212 | 9 (8.0) | 2 (16.7) | 0.285 |
| anosmia / ageusia | 37 (28.0) | 4 (26.7) | 1.000 | 49 (37.4) | 8 (53.3) | 0.270 | 52 (45.2) | 9 (69.2) | 0.143 | 46 (40.7) | 8 (66.7) | 0.125 |
| gastrointest. symptoms | 22 (16.4) | 2 (13.3) | 1.000 | 22 (16.8) | 3 (21.4) | 0.710 | 11 (9.6) | 1 (7.7) | 1.000 | 8 (7.1) | 1 (8.3) | 1.000 |
| sore throat | 41 (30.6) | 2 (13.3) | 0.233 | 21 (16.3) | 3 (21.4) | 0.705 | 7 (6.1) | 4 (30.8) | 0.015 | 4 (3.6) | 4 (33.3) | 0.003 |

*Significant values are marked in red.*

.

Table S4 Number of symptoms by days 1,5,7,8,10,14.

| number of symptoms (incl. fever) | day 1 (n=111) | day 5 (n=102) | day 7 (n=86) | day 8 (n=70) | day 10 (n=59) | day 14 (n=55) |
|---|---|---|---|---|---|---|
| | % (n) | % (n) | % (n) | % (n) | % (n) | % (n) |
| 0 | 0.9 (1) | 6.9 (7) | 16.3 (14) | 14.3 (10) | 18.6 (11) | 40 (22) |
| 1 | 9.9 (11) | 20.6 (21) | 24.4 (21) | 20.0 (14) | 30.5 (18) | 27.3 (15) |
| 2 | 10.8 (12) | 12.7 (13) | 11.6 10) | 18.6 (13) | 11.9 (7) | 9.1 (5) |
| 3 | 17.1 (19) | 17.6 (18) | 4.7 (3) | 7.1 (5) | 8.5 (5) | 5.5 (3) |
| 4 | 16.2 (18) | 7.8 (4) | 10.5 (9) | 10.0 (7) | 10.2 (6) | 10.9 (6) |
| 5 | 17.1 (19) | 10.8 (11) | 10.5 (9) | 8.6 (6) | 5.1 (3) | 3.6 (2) |
| 6 | 12.6 (14) | 12.7 (13) | 14.0 (12) | 10.0 (7) | 6.8 (4) | 1.8 (1) |
| 7 | 8.1 (9) | 2.9 (3) | 3.5 (3) | 7.1 (5) | 5.1 (3) | - |
| 8 | 4.5 (5) | 2.9 (3) | 3.5 (3) | 4.3 (3) | 3.4 (2) | 1.8 (1) |
| 9 | 1.8 (2) | 2.9 (3) | 1.2 (1) | - | - | - |
| 10 | 0.9 (1) | 1.0 (1) | - | - | - | - |
| 11 | - | 1.0 (1) | - | - | - | - |

*Colour coding according to frequency (descending): dark red – red - dark yellow – yellow - grey.*

Table S5  Number of symptoms in comparison hospitalized to non-hospitalized patients

| | no (n=138) | yes (n=16) | p |
|---|---|---|---|
| symptomatic at day 1 (median [IQR]) | 4.50 [3.00, 6.00] | 5.00 [4.75, 7.25] | 0.153 |
| symptomatic at day 5 (median [IQR]) | 3.00 [2.00, 5.75] | 7.00 [4.00, 8.00] | 0.001 |
| symptomatic at day 7 (median [IQR]) | 2.00 [1.00, 5.00] | 6.00 [4.75, 7.00] | <0.001 |
| symptomatic at day 8 (median [IQR]) | 2.00 [0.25, 4.00] | 5.00 [3.75, 7.25] | 0.001 |
| symptomatic at day 10 (median [IQR]) | 1.00 [0.00, 3.00] | 4.00 [1.00, 6.25] | 0.009 |

COVID-19 in primary care - symptoms, risk factors

| symptomatic at day 14 (median [IQR]) | 1.00 [0.00, 2.00] | 1.50 [0.00, 3.50] | 0.077 |
|---|---|---|---|
| | | | |

*Significant values are marked in red*

Figure S1 Frequencies of symptoms in the course of the disease